

8 August 2018

ASX ANNOUNCEMENT

Capital Raising – Placement and Share Purchase Plan

1. Placement

Medical Developments International (ASX: MVP) (**Company**) is pleased to advise that it has today successfully secured a placement of 4,250,000 ordinary shares in the Company to a number of sophisticated and wholesale investors at a price of \$4.00 per share, raising \$17m (before costs) (**Placement**).

The new shares to be issued under the Placement will rank equally with existing MVP fully paid ordinary shares on issue. The Placement was conducted in accordance with ASX Listing Rule 7.1.

The expected date of issue of the securities is Tuesday, 14 August 2018.

2. Share Purchase Plan

MVP will now invite existing shareholders to invest in the Company through a Share Purchase Plan (**SPP**) at a purchase price of \$4.00 per share.

Shareholders on the MVP share register at 7.00pm (AEST) on Tuesday, 7 August 2018 (**Record Date**), whose registered address is in Australia or New Zealand will be entitled to subscribe for a minimum of \$500 worth of MVP fully paid ordinary shares, up to a maximum amount of \$[15,000] worth of MVP fully paid ordinary shares (free of brokerage and other transaction costs), subject to the terms and conditions of the SPP.

The number of shares issued under the SPP is capped at 1,250,000, being within 30% of MVP's fully paid ordinary shares on issue. The Board reserves the right in its absolute discretion to withdraw, scale back and/or close the SPP offer early, as well as to accept over-subscriptions up to the overall 30% cap.

The new shares to be issued under the SPP will rank equally with existing MVP fully paid ordinary shares on issue.

Further information in relation to the SPP, including the SPP terms and conditions, will be outlined in a separate SPP offer document (**Offer Document**) which will be despatched to eligible shareholders within the next 10 business days.

3. Indicative timetable

The timetable below is indicative only and subject to change. The Company reserves the right to alter the below dates at its full discretion and without prior notice, subject to the ASX Listing Rules and the Corporations Act. The commencement of trading of new MVP fully paid ordinary shares is subject to confirmation from ASX.

All times below are Melbourne, Australia time.

Event	Date
Record date for the SPP	7 August 2018 (7.00pm)
Announcement date of Placement and SPP	8 August 2018
Expected date of issue of the Placement shares	14 August 2018
Despatch of the Offer Document	22 August 2018
SPP opening date	22 August 2018
SPP closing Date	11 September 2018
Issue of shares under SPP	19 September 2018
SPP shares commence trading on the ASX	20 September 2018

4. Use of funds

Funds raised from the Placement and SPP will be primarily used to:

- progress clinical programs in the UK and Europe and elsewhere;
- continue the CSIRO Advanced Manufacturing Program including related capital expenditure;
- a clinical PK study in Europe;
- new Pentrox inhaler development;
- USA development costs contingency;
- compliance and manufacturing equipment; and
- reduce loan draw down and working capital costs.

As a result of this announcement, MVP will resume trading from the commencement of trading today.

Enquiries:

John Sharman
Chief Executive Officer
Medical Developments International Ltd
03 9547 1888

David Williams
Chairman
Medical Developments International Ltd
0414 383 593



About Pentrox

Penthrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used safely and effectively for more than 30 years in Australia with in excess of 6.0 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, a fast-acting trauma & emergency pain relief product. Penthrox is now approved in over 35 countries including 25 in the EU, Canada, New Zealand, South Africa and the Company expects to be selling into the majority of those countries in FY19. Locally, Penthrox continues its long-established use in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Force, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.